Risk of clinically significant depression in HIV-infected patients: Effect of antiretroviral drugs

HIV Medicine

Volumn 15, Issue 4, 2014, Pages 213-223

  Gutierrez F ^a   Garcia L ^b   Padilla, S ^a   Alvarez D ^c   Moreno, S ^d   Navarro, G ^e   Gómez Sirvent, Jl ^f   Vidal, F ^g   Asensi, V ^h   Masia M ^a  

^a MIGUEL HERNÁNDEZ UNIVERSITY   (Spain)

^b University Hospital of Sant Joan d'Alacant   (Spain)

^c CARLOS III INSTITUTE OF HEALTH   (Spain)

^d HOSPITAL RAMÓN Y CAJAL   (Spain)

^e Parc Tauli Health Corporation   (Spain)

^f HOSPITAL UNIVERSITARIO DE CANARIAS   (Spain)

^g HOSPITAL UNIVERSITARI JOAN XXIII   (Spain)

^h Asturias Central University Hospital   (Spain)

Author keywords

Antiretroviral therapy; Comorbidity; Efavirenz; Neurologic complications; Non AIDS events; Psychiatric events

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; ATAZANAVIR; EFAVIRENZ; LOPINAVIR; NEVIRAPINE; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR;

ADULT; AGE; ANTIVIRAL THERAPY; ARTICLE; DEPRESSION; DISEASE ASSOCIATION; DRUG INDUCED DISEASE; FEMALE; FOLLOW UP; HIGH RISK PATIENT; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; PRIORITY JOURNAL; TREATMENT DURATION;

ANTIRETROVIRAL THERAPY; COMORBIDITY; EFAVIRENZ; NEUROLOGIC COMPLICATIONS; NON-AIDS EVENTS; PSYCHIATRIC EVENTS;

ADULT; ANTI-HIV AGENTS; BENZOXAZINES; DEPRESSION; FEMALE; HIV INFECTIONS; HUMANS; MALE; MIDDLE AGED; POISSON DISTRIBUTION; PROSPECTIVE STUDIES; REVERSE TRANSCRIPTASE INHIBITORS;

EID: 84895090107     PISSN: 14642662     EISSN: 14681293     Source Type: Journal    
DOI: 10.1111/hiv.12104     Document Type: Article

References (37)

1. Kilbourne AM, Justice AC, Rabeneck L, Rodriguez-Barradas M, Weissman S. VACS 3 Project Team. General medical and psychiatric comorbidity among HIV-infected veterans in the post-HAART era. J Clin Epidemiol 2001; 54 (Suppl 1): S22-S28.
2. Justice AC, McGinnis KA, Atkinson JH etal. Psychiatric and neurocognitive disorders among HIV-positive and negative veterans in care: veterans aging cohort five-site study. AIDS 2004; 18 (Suppl 1): S49-S59.
3. Pence BW, Miller WC, Whetten K, Enron JJ, Gaynes BN. Prevalence of DSM-IV-defined mood, anxiety, and substance use disorders in an HIV clinic in the southeastern United States. J Acquir Immune Defic Syndr 2006; 42: 298-306.
4. Ciesla JA, Roberts JE. Meta-analysis of the relationship between HIV infection and risk for depressive disorders. Am J Psychiatry 2001; 158: 725-730.
5. DiMatteo MR, Lepper HS, Croghan TW. Depression is a risk factor for noncompliance with medical treatment: metaanalysis of the effects of anxiety and depression on patient adherence. Arch Intern Med 2000; 160: 2101-2107.
6. Lima VD, Geller J, Bangsberg DR etal. The effect of adherence on the association between depressive symptoms and mortality among HIV-infected individuals first initiating HAART. AIDS 2007; 21: 1175-1183.
7. Ickovics JR, Hamburger ME, Vlahov D etal. Mortality, CD4 cell count decline, and depressive symptoms among HIV-seropositive women: longitudinal analysis from the HIV Epidemiology Research Study. JAMA 2001; 285: 1466-1474.
8. Anastos K, Schneider MF, Gange SJ etal. The association of race, sociodemographic, and behavioral characteristics with response to highly active antiretroviral therapy in women. J Acquir Immune Defic Syndr 2005; 39: 537-544.
9. Parienti JJ, Massari V, Descamps D etal. Predictors of virologic failure and resistance in HIV-infected patients treated with nevirapine or efavirenz-based antiretroviral therapy. Clin Infect Dis 2004; 38: 1311-1316.
10. Cook JA, Grey D, Burke J etal. Depressive symptoms and AIDS-related mortality among a multisite cohort of HIV-positive women. Am J Public Health 2004; 94: 1133-1140.
11. Starace F, Bartoli L, Aloisi MS etal. Cognitive and affective disorders associated to HIV infection in the HAART era: findings from the NeuroICONA study. Cognitive impairment and depression in HIV/AIDS. The NeuroICONA study. Acta Psychiatr Scand 2002; 106: 20-26.
12. Low-Beer S, Chan K, Yip B etal. Depressive symptoms decline among persons on HIV protease inhibitors. J Acquir Immune Defic Syndr 2000; 23: 295-301.
13. O'Mahony SM, Myint AM, Steinbusch H, Leonard BE. Efavirenz induces depressive-like behaviour, increased stress response and changes in the immune response in rats. Neuroimmunomodulation 2005; 12: 293-298.
14. Muñoz-Moreno JA, Fumaz CR, Ferrer MJ etal. Neuropsychiatric symptoms associated with efavirenz: prevalence, correlates, and management. A neurobehavioral review. AIDS Rev 2009; 11: 103-109.
15. Gazzard B, Balkin A, Hill A. Analysis of neuropsychiatric adverse events during clinical trials of efavirenz in antiretroviral-naive patients: a systematic review. AIDS Rev 2010; 12: 67-75.
16. Clifford DB, Evans S, Yang Y, Acosta EP, Ribaudo H, Gulick R. Long-term impact of efavirenz on neuropsychological performance and symptoms in HIV-infected individuals (ACTG 5097s). HIV Clin Trials 2009; 10: 343-355.
17. Lochet P, Peyriere H, Lotthe A, Mauboussin JM, Delmas B, Reynes J. Long-term assessment of neuropsychiatric adverse reactions associated with efavirenz. HIV Med 2003; 4: 62-66.
18. Fumaz CR, Muñoz-Moreno JA, Moltó J etal. Long-term neuropsychiatric disorders on efavirenz-based approaches: quality of life, psychologic issues, and adherence. J Acquir Immune Defic Syndr 2005; 38: 560-565.
19. Clifford DB, Evans S, Yang Y etal. Impact of efavirenz on neuropsychological performance and symptoms in HIV-infected individuals. Ann Intern Med 2005; 143: 714-721.
20. Gutiérrez F, Navarro A, Padilla S etal. Prediction of neuropsychiatric adverse events associated with long-term efavirenz therapy using therapeutic drug monitoring. Clin Infect Dis 2005; 41: 1648-1653.
21. European Agency for the Evaluation of Medicinal Products. European Public Assessment Report: summary of product characteristics, SUSTIVA. 2009. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000249/WC500058311.pdf (accessed 11 September 2013).
22. Marcellin F, Moh R, Carrieri MP etal. Depressive symptoms and exposure to efavirenz in West African HIV-infected adults. HIV Clin Trials 2008; 9: 445-447.
23. Journot V, Chene G, De Castro N etal. ALIZE Study Group. Use of efavirenz is not associated with a higher risk of depressive disorders: a substudy of the randomized clinical trial ALIZE-ANRS 099. Clin Infect Dis 2006; 42: 1790-1799.
24. Masiá M, Padilla S, Alvarez D etal. Risk, predictors, and mortality associated with non-AIDS events in newly diagnosed HIV-infected patients: role of antiretroviral therapy. AIDS 2013; 27: 181-189.
25. Sobrino-Vegas P, Gutiérrez F, Berenguer J etal. The Cohort of the Spanish HIV Research Network (CoRIS) and its associated biobank; organizational issues, main findings and losses to follow-up. Enferm Infecc Microbiol Clin 2011; 29: 645-653.
26. Barak O, Goshen I, Ben-Hur T, Weidenfeld J, Taylor AN, Yirmiya R. Involvement of brain cytokines in the neurobehavioral disturbances induced by HIV-1 glycoprotein120. Brain Res 2002; 933: 98-108.
27. Lawson MA, Kelley KW, Dantzer R. Intracerebroventricular administration of HIV-1 Tat induces brain cytokine and indoleamine 2, 3-dioxygenase expression: a possible mechanism for AIDS comorbid depression. Brain Behav Immun 2011; 25: 1569-1575.
28. Dantzer R, O'Connor JC, Freund GG, Johnson RW, Kelley KW. From inflammation to sickness and depression: when the immune system subjugates the brain. Nat Rev Neurosci 2008; 9: 46-56.
29. Dantzer R, O'Connor JC, Lawson MA, Kelley KW. Inflammation-associated depression: from serotonin to kynurenine. Psychoneuroendocrinology 2011; 36: 426-436.
30. Fu X, Zunich SM, O'Connor JC, Kavelaars A, Dantzer R, Kelley KW. Central administration of lipopolysaccharide induces depressive-like behavior in vivo and activates brain indoleamine 2, 3 dioxygenase in murine organotypic hippocampal slice cultures. J Neuroinflammation 2010; 7: 43.
31. O'Connor JC, Lawson MA, André C etal. Induction of IDO by bacille Calmette-Guerin is responsible for development of murine depressive-like behavior. J Immunol 2009; 182: 3202-3212.
32. O'Connor JC, Lawson MA, Andre C etal. Lipopolysaccharide-induced depressive-like behavior is mediated by indoleamine 2, 3-dioxygenase activation in mice. Mol Psychiatry 2009; 14: 511-522.
33. Appay V, Sauce D. Immune activation and inflammation in HIV-1 infection: causes and consequences. J Pathol 2008; 214: 231-241.
34. Fuchs D, Möller AA, Reibnegger G, Stöckle E, Werner ER, Wachter H. Decreased serum tryptophan in patients with HIV-1 infection correlates with increased serum neopterin and with neurologic/psychiatric symptoms. J Acquir Immune Defic Syndr 1990; 3: 873-876.
35. Waters L, Fisher M, Winston A etal. A phase IV, double-blind, multicentre, randomized, placebo-controlled, pilot study to assess the feasibility of switching individuals receiving efavirenz with continuing central nervous system adverse events to etravirine. AIDS 2011; 25: 65-71.
36. Nguyen A, Calmy A, Delhumeau C etal. Swiss HIV Cohort Study. A randomized crossover study to compare efavirenz and etravirine treatment. AIDS 2011; 25: 57-63.
37. Nguyen A, Calmy A, Delhumeau C etal. A randomized cross-over study to compare raltegravir and efavirenz (SWITCH-ER study). AIDS 2011; 25: 1481-1487.